JP7628716B2 - １－［１－（４－ベンジルオキシ－３，５－ジフルオロ－ベンゾイル）－４－フルオロ－ピロリジン－２－カルボニル］－ピロリジン－２－カルボニトリル - Google Patents

１－［１－（４－ベンジルオキシ－３，５－ジフルオロ－ベンゾイル）－４－フルオロ－ピロリジン－２－カルボニル］－ピロリジン－２－カルボニトリル Download PDF

Info

Publication number
JP7628716B2
JP7628716B2 JP2022581707A JP2022581707A JP7628716B2 JP 7628716 B2 JP7628716 B2 JP 7628716B2 JP 2022581707 A JP2022581707 A JP 2022581707A JP 2022581707 A JP2022581707 A JP 2022581707A JP 7628716 B2 JP7628716 B2 JP 7628716B2
Authority
JP
Japan
Prior art keywords
fine
inter
black
perfectly
brought
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022581707A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023533932A5 (enExample
JP2023533932A (ja
Inventor
クルア、テレサ タラゴ
コサノ、ロヘル プラデス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Accure Therapeutics SL
Original Assignee
Accure Therapeutics SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Accure Therapeutics SL filed Critical Accure Therapeutics SL
Publication of JP2023533932A publication Critical patent/JP2023533932A/ja
Publication of JP2023533932A5 publication Critical patent/JP2023533932A5/ja
Application granted granted Critical
Publication of JP7628716B2 publication Critical patent/JP7628716B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
JP2022581707A 2020-07-07 2021-07-06 １－［１－（４－ベンジルオキシ－３，５－ジフルオロ－ベンゾイル）－４－フルオロ－ピロリジン－２－カルボニル］－ピロリジン－２－カルボニトリル Active JP7628716B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20382606.0 2020-07-07
EP20382606 2020-07-07
PCT/EP2021/068577 WO2022008477A1 (en) 2020-07-07 2021-07-06 1-[1-(4-benzyloxy-3,5-difluoro-benzoyl)-4-fluoro-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile

Publications (3)

Publication Number Publication Date
JP2023533932A JP2023533932A (ja) 2023-08-07
JP2023533932A5 JP2023533932A5 (enExample) 2024-07-01
JP7628716B2 true JP7628716B2 (ja) 2025-02-12

Family

ID=71607883

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022581707A Active JP7628716B2 (ja) 2020-07-07 2021-07-06 １－［１－（４－ベンジルオキシ－３，５－ジフルオロ－ベンゾイル）－４－フルオロ－ピロリジン－２－カルボニル］－ピロリジン－２－カルボニトリル

Country Status (19)

Country Link
US (1) US12459891B2 (enExample)
EP (1) EP4178945B1 (enExample)
JP (1) JP7628716B2 (enExample)
KR (1) KR20230035604A (enExample)
CN (1) CN117545738A (enExample)
AU (1) AU2021303440A1 (enExample)
BR (1) BR112023000335A2 (enExample)
CA (1) CA3185064A1 (enExample)
ES (1) ES2997164T3 (enExample)
HR (1) HRP20241527T1 (enExample)
HU (1) HUE068953T2 (enExample)
IL (1) IL299035B1 (enExample)
MA (1) MA60250B1 (enExample)
MX (1) MX2023000261A (enExample)
RS (1) RS66215B1 (enExample)
SM (1) SMT202400460T1 (enExample)
TW (1) TWI893162B (enExample)
WO (1) WO2022008477A1 (enExample)
ZA (1) ZA202213708B (enExample)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006516557A (ja) 2003-01-03 2006-07-06 オリオン コーポレーション プロリルオリゴペプチダーゼ阻害活性を有する化合物
WO2014072498A1 (en) 2012-11-12 2014-05-15 Universitat De Barcelona 1-[1-(benzoyl)-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile derivatives

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6159938A (en) 1994-11-21 2000-12-12 Cortech, Inc. Serine protease inhibitors comprising α-keto heterocycles
DE19603510A1 (de) 1996-02-01 1997-08-07 Knoell Hans Forschung Ev Die Verwendung von Terrecyclolsäure A und Terrecyclolsäure A-Derivate als neue Inhibitoren der humanen Prolyl-Oligopeptidase
FI20011466A0 (fi) 2001-07-04 2001-07-04 Orion Corp Prolyylioligopeptidaasia inhiboivaa aktiivisuutta omaavia yhdisteitä, niiden valmistusmenetelmiä ja käyttö
FI20031018A0 (fi) 2003-07-04 2003-07-04 Orion Corp Parannus aivovammasta toipumiseen
WO2005027934A1 (ja) 2003-09-24 2005-03-31 Nippon Kayaku Kabushiki Kaisha プロリルオリゴペプチダーゼ阻害剤
US7667044B2 (en) 2003-11-03 2010-02-23 Probiodrug Ag Compounds for the treatment of neurological disorders
ES2302473B1 (es) 2006-12-22 2009-06-12 Universidad De Barcelona Agente terapeutico para el tratamiento del desorden afectivo bipolar en mamiferos.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006516557A (ja) 2003-01-03 2006-07-06 オリオン コーポレーション プロリルオリゴペプチダーゼ阻害活性を有する化合物
WO2014072498A1 (en) 2012-11-12 2014-05-15 Universitat De Barcelona 1-[1-(benzoyl)-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile derivatives

Also Published As

Publication number Publication date
ZA202213708B (en) 2024-04-24
IL299035A (en) 2023-02-01
TWI893162B (zh) 2025-08-11
SMT202400460T1 (it) 2025-01-14
EP4178945B1 (en) 2024-08-28
BR112023000335A2 (pt) 2023-01-31
US12459891B2 (en) 2025-11-04
AU2021303440A1 (en) 2023-02-02
CN117545738A (zh) 2024-02-09
EP4178945C0 (en) 2024-08-28
US20230250058A1 (en) 2023-08-10
WO2022008477A1 (en) 2022-01-13
ES2997164T3 (en) 2025-02-14
EP4178945A1 (en) 2023-05-17
CA3185064A1 (en) 2022-01-13
HUE068953T2 (hu) 2025-02-28
MX2023000261A (es) 2023-04-13
JP2023533932A (ja) 2023-08-07
MA60250B1 (fr) 2024-11-29
TW202216689A (zh) 2022-05-01
KR20230035604A (ko) 2023-03-14
HRP20241527T1 (hr) 2025-01-03
IL299035B1 (en) 2026-03-01
RS66215B1 (sr) 2024-12-31

Similar Documents

Publication Publication Date Title
JP7628802B2 (ja) 半導体装置及び電子機器
Levine In search of Sugihara: the elusive Japanese diplomat who risked his life to rescue 10,000 Jews from the Holocaust
Delany Trouble on Triton: An Ambiguous Heterotopia
Carr On edge: Performance at the end of the twentieth century
JP7628732B2 (ja) 金属酸化物半導体及び薄膜トランジスタと応用
Lourie Sakharov: a biography
JP7628797B2 (ja) 積層体の製造方法、塗装物の製造方法、接合構造体の製造方法、熱転写シート、及び積層体
JP7628744B2 (ja) 電子タバコカートリッジ
Eliade Autobiography, Volume 1: 1907-1937, Journey East, Journey West
JP7628691B2 (ja) 幼若ブタ由来幹細胞およびその調製方法
JP7628689B2 (ja) 血管内皮（前駆）細胞を含む細胞集団、その製造方法、及び医薬組成物
Spiegel Sidney Lumet: A Life
JP7628795B2 (ja) 炭化珪素単結晶の製造方法及び製造装置
Galer Beryl: The Making of a Disability Activist
JP7628731B2 (ja) 検体に含まれる成分の含有量比の推定方法、組成推定装置、及び、プログラム
JP7628807B2 (ja) 安定同位体濃縮装置
JP7628718B2 (ja) 車両情報処理装置および車両情報処理プログラム
Kirshner Sex work in popular culture
Williams Voice of the Whirlwind
JP7628755B2 (ja) 基板保持部材
JP7628694B2 (ja) 熱収縮性フィルムを利用したタイダイ染
JP7628791B2 (ja) 室内環境管理システム
JP7628706B2 (ja) 給湯器の配管連結構造
Carson Parting ways: new rituals and celebrations of life's passing
JP7628739B1 (ja) 画像処理装置、画像処理システム、画像処理方法およびそのプログラム

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240621

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240621

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250114

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250123

R150 Certificate of patent or registration of utility model

Ref document number: 7628716

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150